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Abstract
Purpose The insulin-like growth factor (IGF) system is
modifiable by diet and lifestyle, and has been linked to
prostate cancer development and progression.
Methods We conducted a prospective cohort study of 621
men diagnosed with localized prostate cancer to investigate
the associations of dietary and lifestyle changes with post-
diagnosis circulating levels of IGF-I and IGFBP-3. We
used analysis of covariance to estimate the associations,
controlling for baseline IGF-I or IGFBP-3, respectively.
Results Mean IGF-I levels were 6.5% (95% CI -12.8,
-0.3%, p = 0.04) lower in men who decreased their
protein intake after diagnosis compared to men who did not
change. Men who changed their fruit and vegetable intake
had lower IGF-I levels compared to non-changers [De-
creased intake: -10.1%, 95% CI -18.4, -1.8%, p = 0.02;
Increased intake: -12.0%, 95% CI -18.4, -1.8%,
p = 0.002]. IGFBP-3 was 14.6% (95% CI -24.5, -4.8%,
p = 0.004) lower in men who achieved a healthy body
mass index after diagnosis. Men who became inactive had
9.5% higher average IGF-I levels (95% CI 0.1, 18.9%,
p = 0.05).
Conclusions Decreased protein intake and body mass
index, and increased physical activity and fruit and veg-
etable intake, following a prostate cancer diagnosis were
associated with reduced post-diagnosis serum IGF-I and
IGFBP-3. Counterintuitively, reduced fruit and veg-
etable intake was also associated with reduced IGF-I, but
with weak statistical support, possibly implicating chance.
If confirmed in other studies, our findings may inform
potential lifestyle interventions in prostate cancer. ProtecT
was registered at International Standard Randomised
Controlled Trial Registry, http://isrctn.org as
ISRCTN20141297.
Keywords Prostatic neoplasms  Diet  Lifestyle  Insulin-
like growth factors  Post-diagnosis
Introduction
The insulin-like growth factor (IGF) system has been
implicated in the etiology and progression of various can-
cers, including prostate cancer [1–3]. Specifically, IGF-I is
associated with increased risk of prostate cancer and higher
risk of prostate cancer-specific mortality in men with
advanced cancer [2, 3]. It is a potent mitogen that promotes
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cell proliferation, metabolism and differentiation, and
inhibits apoptosis [1]. About 90% of circulating IGF-I is
bound to IGF binding protein-3 (IGFBP-3) [1], which
regulates the bioavailability of IGF-I and suppresses its
effects by inhibiting IGF-I binding to IGF cell-surface
receptors. However, epidemiological evidence on
IGFBP3’s relationship with prostate cancer is mixed [2].
Circulating IGF levels are nutritionally regulated and
may mediate the observed effects of diet on prostate can-
cer, including lycopene-rich foods, plant foods, calcium,
and dairy products [4, 5]. It is well established that IGF-I is
elevated by protein and energy intake in malnourished
individuals [6]. Dairy and calcium intakes are positively
and consistently associated with IGF-I in epidemiological
studies [7, 8], with randomized clinical trials showing
increased IGF-I levels with higher milk intake [9, 10].
Conversely, lycopene-rich foods [11] and plant foods
[12, 13] have been inversely linked to IGF-I. Associations
of the IGF system with smoking, alcohol, and physical
activity are uncertain [1, 12, 14–16], while several studies
have reported an inverted U-shaped relationship between
body mass index (BMI) and IGF-I [17, 18].
As far as we know, no study has examined the longi-
tudinal association of dietary and lifestyle changes with
circulating IGF levels after a prostate cancer diagnosis.
Most studies have been cross-sectional and involved
cancer-free populations [7, 8, 12, 19]. One study inves-
tigated the 8-year associations of IGF peptides with life-
style factors, but in young men who were cancer-free
[15]. Here we investigate the association of changes in
dietary intake or adherence to dietary and lifestyle rec-
ommendations with post-diagnosis circulating levels of
IGF-I and IGFBP-3 in men diagnosed with prostate can-
cer in the Prostate testing for cancer and Treatment
(ProtecT) randomized trial [20].
Materials and methods
Study population
ProtecT is a population-based randomized controlled trial
investigating the effectiveness of treatments for PSA-de-
tected localized prostate cancer [20]. Between 2001 and
2009, 228,966 men aged 50–69 years registered at general
practices in nine UK cities were invited to attend a prostate
check clinic. Over 82,000 men had a prostate-specific
antigen (PSA) test, and consent was sought from men to
provide additional blood samples for research purposes.
They were also given a diet, health, and lifestyle (DHL)
questionnaire to complete before receipt of their PSA
results. Men with raised PSA (C3 and \20 ng/mL;
n = 8,566) were invited for repeated PSA test and a 10
core-transrectal ultrasound-guided biopsy. Tumors were
assigned a Gleason score and cancers were staged using the
tumor node metastasis (TNM) system.
Of the 7,414 men who underwent biopsy, 6,181 were
given a DHL questionnaire at the prostate check clinic and
5,055 returned it (Fig. 1). Overall, 1,872 men were diag-
nosed with localized prostate cancer (T1-T2, NX, M0), of
whom 1,518 were sent a follow-up DHL questionnaire
between 2007 and 2010 with a mean follow-up time of
17 months. Blood samples were also collected at annual
follow-up appointments from men who provided consent.
We excluded men who did not return follow-up DHL
questionnaires (n = 238), did not have baseline serum
IGF-I or IGFBP-3 measurement (n = 169), or did not have
blood collected within ±6 months of the follow-up DHL
questionnaire return date (n = 455). One man had a
markedly raised IGF-I (617.0 ng/mL) and IGFBP-3
(8347.0 ng/mL) and was excluded. We also excluded men
who left the DHL questionnaires blank (n = 11), or
reported total energy intake \800 or [4000 kcal/day
(n = 25) [21]. This resulted in 619 men and 607 men for
the IGF-I and IGFBP-3 analyses, respectively. Study par-
ticipants gave informed consent for the use of their data for
research purposes. The Trent Multicentre Research Ethics
Committee approved the ProtecT trial and the associated
ProMPT study.
Data collection
Trained nurses measured men’s weight at the prostate
check clinic according to a standard protocol. If unavail-
able, self-reported weight was used (n = 44). Weight was
self-reported only at follow-up. Height was self-reported at
baseline and follow-up. BMI was derived as weight over
height squared (kg/m2). Godin’s Leisure Time Physical
Activity questionnaire was used to assess physical activity
[22]. Physical activity was computed as number of times
per week of moderate and strenuous exercise. Alcohol
intake was estimated based on the number of units of
spirits, wine, or beer consumed and the amount of alcohol
(g) per drink. For smoking, we categorized men as never,
former, and current smokers.
Dietary questionnaire
Dietary intake in the past 12 months was assessed using a
validated 114 item-food frequency questionnaire (FFQ)
adapted from the UK arm of the EPIC study [23]. Men
reported frequency of intake for each food item across nine
mutually exclusive categories, ranging from ‘‘never or less
than once per month’’ to ‘‘six or more times per day.’’ The
assignment of portion size in grams for each food item was
based on UK food portion sizes [24], food weights derived
878 Cancer Causes Control (2017) 28:877–888
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from a 7-day diet diary from a sub-sample of participants in
ProtecT, and data from the Carnegie survey of diet and
health [25]. Food intake was computed as the product of
frequency of intake and portion size. Nutrient intake was
derived by multiplying the frequency of intake by the
nutrient content per portion of food, using nutrient values
from the composition tables of McCance and Widdowson,
and its supplements [26]. Refer to Supplementary Material
1 for definition of dairy products, fruits and vegetables, and
foods rich in lycopene.
Dietary exposures were selected a priori based on their
association with circulating IGFs or prostate cancer risk
from the published literature and the World Cancer
Research Fund and the American Institute for Cancer
Research (WCRF/AICR) second expert report [4]. They
include total energy intake, protein, dairy protein, dairy
products, calcium, foods rich in lycopene, non-starch
polysaccharide (NSP), and fruits and vegetables. Lifestyle
exposures of interest were BMI, physical activity, alcohol
intake and smoking status.
Since there were no recommended absolute intakes for
total energy, total protein, dairy protein, and dairy prod-
ucts, we divided men into tertiles of baseline intake: low,
medium, and high (Table 2), and categorized follow-up
intake using the same cut-offs. We grouped men into three
‘change’ categories: no/minimal change (i.e., same cate-
gory at baseline and follow-up assessments), decreased
intake (high to low; or high to medium; or medium to low),
and increased intake (low to medium; low to high; or
medium to high). Where dietary or lifestyle public health
recommendations were available, we categorized men into
two categories based on their level of adherence (adherent
7414 recruited to ProtecT with raised 
PSA
6181 given baseline DHL to complete
5055 returned baseline DHL
Prostate biopsy and diagnosis
1872 localised prostate cancer
1518 sent a follow-up DHL  
1280 returned follow-up DHL
1111 baseline IGF measurements 
656 blood collected ± 6 months of follow-
up DHL
619 in final IGF-I analysis 607 in final IGFBP-3 analysis 
11 left DHL blank        
25 reported extreme energy intake
1 abnormal IGF measurement
455 blood not collected ± 6 months 
of follow-up DHL 
169 no baseline IGF measurements         
238 did not return follow-up DHL     
2354 biopsy negative
691 HGPIN/ASAP
138 advanced prostate cancer
Fig. 1 Flow diagram of
participants included in
analysis. PSA prostate-specific
antigen (C3.0 and\20.0 ng/
mL). DHL diet, health, and
lifestyle, HGPIN high-grade
prostatic intraepithelial
neoplasia, ASAP atypical small
acinar proliferation
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vs. non-adherent) (Table 2). The cut-off criteria were
derived from the WCRF/AICR second expert report for
calcium, BMI, physical activity, and alcohol [4], and the
Health Professionals Study for tomato and tomato products
[27]. Cut-offs for non-starch polysaccharides [28] and
fruits and vegetables [29] concur with UK dietary guide-
lines. We grouped men into four categories: non-adherent
(NAd, i.e., non-adherent before and after diagnosis), non-
adherent to adherent (NAd?Ad, i.e., men who became
more ‘healthy’ after diagnosis), adherent to non-adherent
(Ad?NAd, i.e., men who became less ‘healthy’ after
diagnosis), and adherent (Ad, i.e., adherent before and after
diagnosis).
Blood collection and IGF assays
Non-fasted blood samples were drawn from men at
recruitment (pre-diagnosis) between 2003 and 2008, and at
annual follow-up appointments between 2007 and 2010.
The samples were left to stand at room temperature and
then centrifuged at approximately for 20 min to extract
serum. They were kept at 5 C during transportation to a
laboratory, where they were aliquoted for storage at
-80 C within 36 h of collection. Baseline and follow-up
IGF-I and IGFBP-3 assays were carried out in JMPH’s
laboratory by staff blinded to dietary and lifestyle data
using an in-house radio-immunoassay [30, 31], which
measures total IGF-I and IGFBP-3, including all forms that
have undergone minor fragmentation. Measurements were
performed in triplicates and an average was computed for
analyses.
Baseline serum samples were assayed between 2007 and
2010 to investigate the associations of IGFs and IGFBPs
with prostate cancer risk in a case–control study nested
within ProtecT [32]. Mean intra-assay coefficients of
variation for baseline IGF-I and IGFBP-3 were 7.4 and
8.9%, and mean inter-assay coefficients of variation were
11.3 and 12.5%. All follow-up serum samples were
assayed in 2014. Mean intra-assay coefficients of variation
for follow-up IGF-I and IGFBP-3 were 7.6 and 6.8%, and
mean inter-assay coefficients of variation were 10.0 and
10.5%.
Statistical analysis
Serum IGF-I and IGFBP-3 were approximately normally
distributed. We used analysis of covariance (ANCOVA) to
estimate associations of dietary and lifestyle changes with
post-diagnosis IGF-I and IGFBP-3 separately (see Sup-
plementary Material 1) [33, 34]. All models were adjusted
for baseline IGF values, baseline dietary, or lifestyle
exposure of interest, baseline age, and follow-up time; for
dietary exposures, the models were also adjusted for the
difference in baseline and follow-up total energy intake
(kcal/day) (Model 1 in Tables 3, 4, 5).
We compared the basic ANCOVA models with the
models additionally adjusted for the following confounding
factors identified a priori: height (m), self-reported dia-
betes, occupational class, prostate cancer treatment
received, and cancer grade. For the purpose of this analysis,
tumors with Gleason score of B6 were defined as low, and
C7 as high, grade. For dietary exposures, we also assessed
potential confounding by baseline smoking status, dietary
supplement intake, change in BMI, physical activity, and
alcohol intake. However, most of these additional variables
did not confound any of the observed associations, and
only treatment received and cancer grade were added (in
addition to the variables listed above in Model 1) to the
fully adjusted regression models (Model 2 in Tables 3, 4,
5). Estimates from the fully adjusted regression models
were presented as mean percentage difference of follow-up
IGF-I or IGFBP-3, and are used to predict mean post-di-
agnosis IGF-I or IGFBP-3 levels for each category of pre-
to post-diagnosis change in dietary or lifestyle behaviors.
We estimated the Bonferroni correction for multiple testing
based on the 24 tests carried out. All statistical analyses
were performed using Stata v12.1 (StataCorp, College
Station, TX USA).
Results
Our study population was predominantly White with an
average age of 62 years, and a mean BMI of 27.1 kg/m2 at
recruitment (Table 1). The mean IGF-I and IGFBP-3 levels
were 22.0 nmol/mL (standard deviation (SD): 7.1 nmol/
mL) and 160.2 nmol/mL (SD: 34.5 nmol/mL), respec-
tively. The majority of the men were diagnosed with low
grade cancer (72.7%). Only a small proportion of men had
a family history of prostate cancer (8.7%) or had diabetes
(5.3%), and 52.3% of the men in the study reported taking
dietary supplements.
Table 2 shows the cut-off criteria for categorizing
dietary intake and adherence to dietary and lifestyle rec-
ommendations pre- and post-diagnosis, along with the
proportion of men in each category. Intake of total energy,
non-starch polysaccharide, and fruits and vegetables re-
mained largely the same before and after diagnosis. There
was a decrease in protein and dairy product intake post-
diagnosis: the proportion of men who had high protein
intake decreased by 3.9%, and there were 4.5% fewer men
with a high intake of dairy products. The reduction in
protein intake may in part be due to a smaller contribution
of dairy-derived protein (4.9% decrease in high intake of
dairy protein post-diagnosis). Conversely, men increased
their consumption of foods rich in lycopene following a
880 Cancer Causes Control (2017) 28:877–888
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diagnosis. There was a 2.5% increase in men who had over
10 servings of tomatoes and tomato products per week;
adherence to the physical activity recommendation also
increased by about 3% following a diagnosis. There was a
2.2% fall in the proportion of overweight or obese men.
Some men (2%) quit smoking following a prostate cancer
diagnosis, but alcohol consumption largely remained
unchanged.
Table 3 presents the associations of changes in total
energy, total protein, dairy protein, and dairy product
intake with IGF-I and IGFBP-3 levels following a pros-
tate cancer diagnosis. Average IGF-I levels were 6.5%
(95% CI -12.8, -0.3%, p = 0.04) lower in men who
decreased their protein intake compared to men who did
not change (minimal change). None of the dietary expo-
sures we investigated were associated with post-diagnosis
IGFBP-3.
Table 4 shows the associations of changes in adherence
to dietary recommendations with IGF-I and IGFBP-3 levels
following a prostate cancer diagnosis. Men who consumed
\5 portions/day of fruits and vegetables before diagnosis,
but increased to C5 after their diagnosis (NAd?Ad), had
post-diagnosis IGF-I levels that were on average 12.0%
(95% CI -20.1, -3.9%; p = 0.002) lower than those who
did not change and consumed \5 portions/day (NAd).
Average post-diagnosis IGF-I levels were also lower
among men who had C5 portions/day of fruits and veg-
etables before diagnosis but decreased to\5 after diagnosis
(Ad?NAd: -10.1%, 95% CI -18.4, -1.8%, p = 0.02).
Adherence to the fruits and vegetables recommendation
before and after diagnosis (Ad) was also linked to post-
diagnosis IGF-I levels that were 8.8% lower on average
(95% CI -15.8, -1.8, p = 0.01). Conversely, post-diag-
nosis serum IGFBP-3 levels were not associated with
changes in adherence to recommendations on calcium,
tomatoes and tomato products, non-starch polysaccharide,
or fruits and vegetables.
Table 5 presents the associations of lifestyle changes
with IGF-I and IGFBP-3 levels following a prostate cancer
diagnosis. There was weak evidence that men who were
active before diagnosis but became inactive after their
diagnosis (Ad?NAd) had post-diagnosis IGF-I levels that
were 9.5% higher on average (95% CI 0.1, 18.9%,
p = 0.05) than men who were inactive and did not change.
Average post-diagnosis IGFBP-3 levels were 14.6% (95%
CI -24.5, -4.8%; p = 0.004) lower in men who were
overweight before diagnosis and acquired a healthy BMI
after diagnosis (NAd?Ad). A similar difference was
observed for men who had healthy BMI before and after
diagnosis (Ad vs NAd: -9.2%, 95% CI -16.8, -1.6%;
p = 0.02). Post-diagnosis IGFBP-3 levels were 10.7%
(95% CI -19.3, -2.1%, p = 0.02) lower in men who
adhered to the physical activity recommendation before
and after diagnosis compared to men who were non-ad-
herent and did not change. Finally, the association between
increased fruit and vegetable intake and IGF-I level post-
Table 1 Baseline characteristics of participants
Characteristics n = 619 Mean (SD) or
%
Age at recruitment (years) 619 62.0 (4.9)
Height (m) 610 1.76 (0.06)
Weight (kg) 618 84.2 (12.0)
BMI (kg/m2) 610 27.1 (3.5)
Time since diagnosis (months) 619 17 (9)
Serum IGF concentrations (nmol/mL)
IGF-I 619 22.0 (7.1)
IGFBP-3 607 160.2 (34.5)
Ethnicity
White 607 98.1
Others 5 0.8
Unknown 7 1.1
Occupational class
Managerial 273 44.1
Intermediate 99 16.0
Working 238 38.5
Unknown 9 1.4
Family history of prostate cancer
Yes 54 8.7
No 512 82.7
Do not know 41 6.6
Unknown 12 2.0
Diabetes
Yes 33 5.3
No 541 87.4
Unknown 45 7.3
PSA level
\10.0 ng/mL 549 88.7
10.0–20.0 ng/mL 70 11.3
Treatment
Active monitoring 275 44.4
Prostatectomy 176 38.4
Radiotherapy 167 27.0
Other 1 0.2
Gleason gradea
Low (2–6) 450 72.7
High (7–10) 169 27.3
Vitamin/dietary supplement intake
Yes 324 52.3
No 282 45.6
Unknown 13 2.1
a Gleason scores of 2, 3, and 4 were acceptable when the ProtecT trial
was conducted as it was before the 2005 International Society of
Urological Pathology [44]
Cancer Causes Control (2017) 28:877–888 881
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diagnosis was the only finding robust to Bonferroni cor-
rection (i.e., p = 0.05/24; p = 0.002).
Discussion
To our knowledge, our study is the first to assess associa-
tions of changes in dietary and lifestyle behaviors with
circulating IGF-I and IGFBP-3 levels following a diagnosis
of prostate cancer. We observed associations of post-di-
agnosis serum IGF-I and IGFBP-3 levels with changes in
protein intake and changes in adherence to recommenda-
tions on fruits and vegetables, BMI, and physical activity
following a prostate cancer diagnosis.
Unlike most studies [35–37], there were negligible
changes in smoking, non-starch polysaccharide, and fruit
and vegetable intake in our study population. Instead, there
was a small reduction in the proportion of men in the high
Table 2 Dietary intake and adherence to public health recommendations before and after diagnosis
Cut-off points Intake/adherencea Pre-diagnosis
(n = 619)
Post-diagnosis
(n = 619)
p-valuef
n % n %
Total energy 800.0 to\1995.3 kcal/day Low 207 33.4 210 33.9
C1995.3 to\2529.8 kcal/day Medium 206 33.3 208 33.6
C2529.8 to 4000.0 kcal/day High 206 33.3 201 32.5 0.78
Total protein \76.3 g/day Low 207 33.4 215 34.7
C76.3 to\ 97.9 g/day Medium 206 33.3 222 35.9
C97.9 g/day High 206 33.3 182 29.4 0.27
Dairy protein \12.1 g/day Low 207 33.4 240 38.8
C12.1 g to\18.6 g/day Medium 206 33.3 203 32.8
C18.6 g/day High 206 33.3 176 28.4 0.03
Dairy productsb \292.7 g/day Low 207 33.4 233 37.6
C293.7 to\ 439.4 g/day Medium 207 33.4 209 33.8
C439.4 g/day High 205 33.1 177 28.6 0.06
Calcium C700 to\ 1500 mg/day Ad 481 77.7 464 75.0
\700 or C 1500 mg/day Non-Ad 138 22.3 155 25.0 0.18
Tomato productsb,c [10 servings/week Ad 56 9.0 71 11.5
B10 servings/week Non-Ad 563 91.0 548 88.5 0.09
Non-starch polysaccharides C18 g/day Ad 380 61.4 385 62.2
\18 g/day Non-Ad 239 38.6 234 37.8 0.70
Fruits and vegetablesd,e C5 portions/day Ad 355 57.4 353 57.0
\5 portions/day Non-Ad 264 42.6 266 43.0 0.87
Body mass indexe C18.5 to\25 kg/m2 Ad 167 28.5 180 30.7
C25 kg/m2 Non-Ad 419 71.5 406 69.3 0.09
Physical activityb,e C7 times/week Ad 165 29.1 183 32.3
\7 times/week Non-Ad 402 70.9 384 67.7 0.16
Alcohole B20 g/day Ad 351 57.5 353 57.9
[20 g/day Non-Ad 259 42.5 257 42.1 0.86
Smoking statuse Never n/a 256 42.1 255 41.9
Former n/a 295 48.4 307 50.4
Current n/a 58 9.5 47 7.7 0.09
a Ad Adherence, Non-Ad Non-adherence
b For definition of dairy products, tomato products, and physical activity, refer to Methods and Supplementary Material 1
c Includes fresh tomatoes
d 1 portion equivalent to 400 g
e Men with complete data only: BMI (n = 586), physical activity (n = 567), alcohol (n = 610), smoking status (n = 609)
f p-Values obtained from McNemar test for binary variables, and likelihood ratio test for 3-level variables
882 Cancer Causes Control (2017) 28:877–888
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dairy intake category (median decrease of 0.5 serving/day
in men who decreased intake) and a slight increase in the
proportion of men who consumed[10 servings/week of
tomatoes and tomato products (median increase of 8.0
servings/week in men who increased intake). This could be
due to a heightened awareness of the link between these
dietary factors and prostate cancer risk since the publica-
tion of the WCRF/AICR second expert report [4]. There
was also a marginal increase in the proportion of men who
adhered to the physical activity or healthy weight recom-
mendation post-diagnosis (mean increase of 5.5 times/
week of moderate to strenuous physical activity, and mean
Table 3 Changes in dietary intake and follow-up IGF level, adjusted for baseline IGF
n Mean change
in intake
Mean follow-up
intake
Mean follow-up
IGFa
Difference (95% CI) in mean follow-up serum IGF
concentration (%)
Model 1b Model 2c
IGF-I (n = 619)
Total energy (kcal/day)
No change 309 -13.5 2294.8 20.3 Ref Ref
Decreased 156 -649.3 1955.1 20.3 -1.2 (-7.0, 4.6) -1.7 (-7.5, 4.1)
Increased 154 661.3 2602.7 20.8 4.3 (-1.5, 10.2) 4.3 (-1.6, 10.1)
Total protein (g/day)
No change 325 0.0 86.6 20.8 Ref Ref
Decreased 158 -26.6 75.8 19.5 -6.5 (-12.9, -0.2) -6.5 (-12.8, -0.3)*
Increased 136 25.4 102.2 20.5 3.7 (-2.9, 10.2) 4.5 (-2.0, 11.1)
Dairy protein (g/day)
No change 351 -0.3 15.5 20.2 Ref Ref
Decreased 160 -7.4 11.9 21.0 3.3 (-2.3, 9.0) 4.1 (-1.5, 9.7)
Increased 108 7.0 19.1 20.1 -0.2 (-6.7, 6.4) 0.2 (-6.3, 6.7)
Dairy productsd (g/day)
No change 372 -10.2 360.1 20.5 Ref Ref
Decreased 148 -181.2 274.7 19.8 -2.3 (-8.1, 3.4) -2.2 (-7.8, 3.5)
Increased 99 179.3 462.3 20.7 2.5 (-4.2, 9.1) 2.0 (-4.6, 8.6)
IGFBP-3 (n = 607)
Total energy (kcal/day)
No change 301 -10.0 2304.7 130.6 Ref Ref
Decreased 154 -648.4 1952.4 133.9 2.7 (-2.7, 8.2) 2.8 (-2.7, 8.2)
Increased 152 660.8 2601.1 130.3 0.4 (-5.1, 5.9) 0.6 (-5.0, 6.1)
Total protein (g/day)
No change 320 0.2 86.8 133.0 Ref Ref
Decreased 157 -26.4 75.9 129.4 -2.2 (-8.2, 3.7) -2.3 (-8.3, 3.7)
Increased 134 25.6 102.1 129.7 -2.2 (-8.4, 4.0) -2.0 (-8.3, 4.2)
Dairy protein (g/day)
No change 344 -0.3 15.4 130.1 Ref Ref
Decreased 156 -7.4 12.0 131.5 1.8 (-3.6, 7.1) 2.0 (-3.3, 7.4)
Increased 107 7.0 19.1 135.3 3.1 (-3.0, 9.2) 3.0 (-3.1, 9.2)
Dairy productsd (g/day)
No change 367 -11.0 360.7 130.7 Ref Ref
Decreased 143 -183.8 274.3 128.3 -0.4 (-5.8, 5.0) -0.3 (-5.7, 5.1)
Increased 97 180.0 461.9 138.4 5.3 (-0.9, 11.5) 5.2 (-1.1, 11.4)
a Mean predicted from fully adjusted regression model (nmol/mL)
b Adjusted for baseline age, baseline IGF, baseline dietary intake, follow-up time point, and changes in energy intake (except that for total
energy)
c Further adjusted for treatment received and cancer grade
d For definition of dairy products, refer to Supplementary Material 1. * p = 0.04
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Table 4 Changes in adherence to dietary recommendations and follow-up IGF level, adjusted for baseline IGF
n Mean change
in intake
Mean follow-up
intake
Mean follow-up
IGFa
Difference (95% CI) in mean follow-up serum
IGF concentration (%)
Model 1b Model 2c
IGF-I (n = 619)
Calcium (mg/day)
Non-adherent 66 19.5 1038.4 20.0 Ref Ref
Ad?NAd 89 -95.5 944.9 20.7 0.1 (-9.4, 9.5) -0.4 (-9.8, 8.9)
NAd?Ad 72 -23.6 1049.9 19.8 -0.6 (-10.5, 9.2) -0.3 (-10.0, 9.5)
Adherent 392 -19.3 1025.4 20.5 0.7 (-7.0, 8.4) 0.5 (-7.2, 8.1)
Tomato productsd,e (serving/week)
Non-adherent 517 0 4.5 20.7 Ref Ref
Ad?NAd 31 -9.5 6.0 18.5 -14.1 (-28.4, 0.1) -13.8 (-27.9, 0.3)
NAd?Ad 46 9.5 16.0 19.0 -6.3 (-15.3, 2.7) -5.3 (-14.2, 3.7)
Adherent 25 -2.5 15.0 19.9 -3.7 (-19.6, 12.3) -6.2 (-22.1, 9.6)
NSP (g/day)
Non-adherent 153 0.2 13.7 21.1 Ref Ref
Ad?NAd 81 -8.7 15.2 19.4 -4.9 (-13.9, 4.2) -4.6 (-13.5, 4.4)
NAd?Ad 86 8.4 23.0 19.4 -3.9 (-12.3, 4.5) -3.6 (-11.9, 4.8)
Adherent 399 0.3 27.1 20.6 -0.7 (-8.8, 7.5) -0.4 (-8.5, 7.6)
Fruit and vegetablesd (portion/day)
Non-adherent 193 0 3.5 21.6 Ref Ref
Ad?NAd 73 -2.5 4.0 20.2 -10.4 (-18.9, -2.0) -10.1 (-18.4, -1.8)*
NAd?Ad 71 3.0 7.0 18.3 -12.9 (-21.0, -4.7) -12.0 (-20.1, -3.9)***
Adherent 282 0 8.0 20.2 -8.9 (-15.9, -1.8) -8.8 (-15.8, -1.8)**
IGFBP-3 (n = 607)
Calcium (mg/day)
Non-adherent 64 22.5 1056.4 124.7 Ref Ref
Ad?NAd 86 -97.8 943.8 132.6 3.7 (-5.2, 12.6) 3.9 (-5.0, 12.9)
NAd?Ad 72 -23.6 1049.9 126.7 1.3 (-7.9, 10.5) 1.1 (-8.1, 10.4)
Adherent 385 -18.6 1026.3 133.1 5.1 (-2.2, 12.3) 5.0 (-2.2, 12.3)
Tomato productsd,e (serving/week)
Non-adherent 506 0 4.5 132.4 Ref Ref
Ad?NAd 31 -9.5 6.0 137.9 2.0 (-11.3, 15.2) 1.9 (-11.4, 15.2)
NAd?Ad 45 9.5 16.0 124.4 -5.3 (-13.8, 3.1) -5.2 (-13.7, 3.2)
Adherent 25 -2.5 15.0 114.1 -12.5 (-27.4, 2.3) -13.5 (-28.4, 1.5)
NSP (g/day)
Non-adherent 151 0.2 13.7 134.2 Ref Ref
Ad?NAd 77 -8.7 15.3 129.4 -0.6 (-9.1, 8.0) -0.7 (-9.3, 7.8)
NAd?Ad 85 8.3 22.9 128.2 -2.2 (-10.0, 5.6) -2.0 (-9.9, 5.9)
Adherent 294 0.3 27.1 131.3 0.0 (-7.6, 7.7) 0.0 (-7.6, 7.7)
Fruit and vegetablesd (portion/day)
Non-adherent 189 0 3.5 131.6 Ref Ref
Ad?NAd 71 -2.5 4.0 136.2 3.9 (-4.1, 11.9) 4.2 (-3.8, 12.2)
NAd?Ad 69 3.0 7.0 123.7 -2.7 (-10.4, 5.0) -2.3 (-10.1, 5.5)
Adherent 278 0 8.0 131.9 1.4 (-5.2, 8.0) 1.4 (-5.2, 8.1)
a Mean predicted from fully adjusted regression model
b Adjusted for baseline age, baseline IGF, baseline dietary intake, follow-up time point, and changes in energy intake
c Further adjusted for treatment received and cancer grade
d Rounded to the nearest 0.5 serving/week or portion/day
e Includes fresh tomatoes. For definition of tomato products, refer to Supplementary Material 1. NSP non-starch polysaccharides
*p = 0.02, ** p = 0.01, *** p = 0.002
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Table 5 Changes in adherence to lifestyle recommendations and follow-up IGF level, adjusted for baseline IGF
n Mean change Mean at
follow-up
Mean follow-up
IGFa
Difference (95% CI) in mean follow-up serum IGF
concentration (%)b
Model 1b Model 2c
IGF-I (n = 619)
BMI (kg/m2)
Non-adherent 383 -0.2 28.6 20.3 Ref Ref
Ad?NAd 23 1.4 25.7 21.7 3.1 (-10.1, 16.2) 6.6 (-6.6, 19.8)
NAd?Ad 36 -1.8 24.2 20.6 -1.3 (-11.6, 9.1) 0.4 (-9.9, 10.6)
Adherent 144 -0.1 22.9 20.1 -5.7 (-13.7, 2.3) -4.2 (-12.1, 3.8)
Physical activityd (times/week)
Non-adherent 321 0.5 2.5 20.5 Ref Ref
Ad?NAd 65 -5.0 3.5 21.3 10.1 (0.6, 19.7) 9.5 (0.1, 18.9)*
NAd?Ad 83 5.5 8.5 21.2 3.8 (-3.4, 11.0) 3.3 (-3.9, 10.4)
Adherent 100 0.5 10.5 19.6 3.7 (-5.7, 13.1) 4.2 (-5.1, 13.5)
Alcohol intake (g/day)
Non-adherent 199 1.1 45.9 20.2 Ref Ref
Ad?NAd 58 15.6 29.1 19.7 0.4 (-9.7, 10.5) 2.1 (-7.9, 12.1)
NAd?Ad 60 -22.5 11.9 20.3 3.2 (-5.5, 11.8) 5.8 (-2.8, 14.5)
Adherent 293 -0.7 6.3 20.7 6.6 (-1.7, 14.9) 8.0 (-0.2, 16.2)
Smokingd
Never 256 n/a n/a 20.7 Ref Ref
Former 295 n/a n/a 20.1 -1.1 (-6.1, 3.8) -1.1 (-6.0, 3.8)
Current 58 n/a n/a 20.9 -0.2 (-8.5, 8.1) -0.2 (-8.4, 8.1)
IGFBP-3 (n = 607)
BMI (kg/m2)
Non-adherent 377 -0.2 28.6 133.4 Ref Ref
Ad?NAd 22 1.4 25.6 131.4 -7.7 (-20.2, 4.8) -8.2 (-21.0, 4.6)
NAd?Ad 35 -1.8 24.2 123.6 -14.9 (-24.7, -5.1) -14.6 (-24.5, -4.8)***
Adherent 140 -0.1 23.0 126.1 -9.5 (-17.0, -2.0) -9.2 (-16.8, -1.6)**
Physical activityd (times/week)
Non-adherent 311 0 2.5 130.2 Ref Ref
Ad?NAd 64 -5.0 3.5 143.5 3.5 (-5.2, 12.3) 3.5 (-5.2, 12.3)
NAd?Ad 82 5.5 8.5 129.7 -2.4 (-9.0, 4.2) -2.6 (-9.2, 4.0)
Adherent 98 0.5 10.5 126.6 -10.7 (-19.3, -2.1) -10.7 (-19.3, -2.1)**
Alcohol intake (g/day)
Non-adherent 198 0.9 45.5 133.8 Ref Ref
Ad?NAd 57 15.8 29.2 134.8 2.3 (-7.2, 11.7) 2.8 (-6.7, 12.2)
NAd?Ad 60 -22.5 11.9 129.8 -1.1 (-9.2, 6.9) -0.4 (-8.5, 7.7)
Adherent 283 -0.7 6.3 129.3 -2.2 (-9.9, 5.5) -2.0 (-9.7, 5.8)
Smokinge
Never 255 n/a n/a 136.6 Ref Ref
Former 296 n/a n/a 130.1 -0.5 (-5.1, 4.1) -0.5 (-5.1, 4.1)
Current 56 n/a n/a 132.1 -0.0 (-7.9, 7.9) -0.5 (-8.5, 7.6)
a Mean predicted from fully adjusted regression model
b Adjusted for baseline age, baseline IGF, baseline lifestyle exposure, follow-up time point
c Further adjusted for treatment received and cancer grade
d Rounded to the nearest 0.5 times/week
e Baseline smoking status only was evaluated due to minimal change at follow-up. n/a not applicable
*p = 0.05, ** p = 0.02 *** p = 0.004
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reduction of 1.8 kg/m2 in BMI), which is in line with the
findings from several studies [37, 38].
Our finding of a lower average post-diagnosis IGF-I
level in men who reduced their protein intake is supported
by most studies, which found a positive link between
protein intake and IGF-I [6–8]. The decrease in protein
intake in our study may be attributed to a lower intake of
dairy products and decreased protein intake from dairy
sources. It has been postulated that the protein fraction of
dairy (i.e., dairy protein) drives the positive relationship
between IGF-I and dairy intake [8, 10, 39]. However, we
did not observe any associations of changes in dairy pro-
duct or dairy protein intake with post-diagnosis IGF-I or
IGFBP-3.
Men who adhered to the recommendation on fruits and
vegetables (C5 portions/day) post-diagnosis had lower
average IGF-I levels than men who were non-adherent and
did not change. Similarly, men who were adherent to the
recommendation pre- and post-diagnosis had lower IGF-I
levels. High vegetable intake has been linked to lower
circulating levels of IGF-I or higher IGFBP-3 in some
[12, 13, 19] but not all studies [39, 40]. However, IGF-I
levels were also lower in men who decreased their intake to
fewer than five portions a day after a diagnosis in our study.
It is possible that pre-diagnosis diet reflects long-term
dietary intake, so long-term adherence to the recommen-
dation on fruits and vegetables may offset the impact of
lower fruits and vegetables intake after a diagnosis on
circulating IGF-I. Nonetheless, we cannot exclude the
possibility of a chance findings in the context of potential
misclassification of exposure errors, limited power, and
multiple testing.
We did not find any links between changes in lifestyle
factors and post-diagnosis IGF-I, except for physical
activity. Men who were active before diagnosis but became
inactive had higher average post-diagnosis IGF-I levels,
but the strength of evidence was weak. Post-diagnosis
IGFBP-3 was lower in men who met the BMI recom-
mendation (\25.0 kg/m2), especially among men who
were overweight before diagnosis but acquired a healthy
BMI after diagnosis. The positive association between BMI
and IGFBP-3 was previously observed in cancer-free men
in the ProtecT study [17]. IGFBP-3 increased by 63.5 ng/
ml per SD higher in BMI (95% CI -2.69–129.8,
p = 0.06). Conversely, the Coronary Artery Risk Devel-
opment in Young Adults (CARDIA) study found no
association between 8-year changes in BMI and IGFBP-3
[15].
Strengths of our study include its size and population-
based, prospective design. Detection bias was minimized,
as case finding was part of the trial design. There were
standardized records of cancer stage and grade, and types
of treatment. We also have blood samples collected close
to the return date of the follow-up questionnaires
(±6 months). However, most participants were White
European, and there are some ethnic differences in dietary
and lifestyle associations with IGF peptides [15, 19, 41], so
our findings may not be generalizable to other ethnic
groups.
Although we used validated and detailed questionnaires
to minimize measurement error, there will still be some
misclassification of exposures. Compared to food diaries,
FFQ is prone to a greater degree of misclassification
[42, 43], but the effect is likely to be non-differential in our
study as baseline questionnaires were completed by 54.1%
of men before receipt of initial PSA test results, and men
were not given any dietary advice after diagnosis. There-
fore, true associations of dietary and lifestyle changes with
post-diagnosis circulating IGF-I and IGFBP-3 might be
underestimated.
There was variation in baseline and follow-up serum
sample storage time, ranging from 0 to 7 years. Nonethe-
less, storage time was not associated with baseline or fol-
low-up circulating IGF-I and IGFBP-3 in univariable
analyses. Finally, using a conservative Bonferroni multiple
testing penalty would lead to just one strong finding.
However, our study is the first to find such differences in
IGF-I and IGFBP-3 post-diagnosis, and other studies are
needed to replicate our novel findings. To minimize mul-
tiple testing, we had decided a priori on the dietary and
lifestyle variables to be tested and used established dietary
guidelines and lifestyle recommendations for categoriza-
tion where available.
In conclusion, decreased protein intake and BMI, and
increased fruits and vegetables intake and physical activity,
following a prostate cancer diagnosis were associated with
reduced post-diagnosis serum IGF-I and IGFBP-3. As one
of the first studies to identify these links, our findings
warrant confirmation in other studies and may inform
future dietary and lifestyle interventions in men with
prostate cancer.
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